128 related articles for article (PubMed ID: 28903377)
21. Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
Lee WJ; Lee YJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
Melanoma Res; 2018 Oct; 28(5):423-434. PubMed ID: 29634635
[TBL] [Abstract][Full Text] [Related]
22. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
[TBL] [Abstract][Full Text] [Related]
23. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Hino R; Kabashima K; Kato Y; Yagi H; Nakamura M; Honjo T; Okazaki T; Tokura Y
Cancer; 2010 Apr; 116(7):1757-66. PubMed ID: 20143437
[TBL] [Abstract][Full Text] [Related]
24. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
[TBL] [Abstract][Full Text] [Related]
25. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
[TBL] [Abstract][Full Text] [Related]
26. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.
Kostine M; Briaire-de Bruijn IH; Cleven AHG; Vervat C; Corver WE; Schilham MW; Van Beelen E; van Boven H; Haas RL; Italiano A; Cleton-Jansen AM; Bovée JVMG
Oncoimmunology; 2018; 7(2):e1386828. PubMed ID: 29308311
[No Abstract] [Full Text] [Related]
27. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
28. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
Thierauf J; Veit JA; Affolter A; Bergmann C; Grünow J; Laban S; Lennerz JK; Grünmüller L; Mauch C; Plinkert PK; Hess J; Hoffmann TK
Melanoma Res; 2015 Dec; 25(6):503-9. PubMed ID: 26352784
[TBL] [Abstract][Full Text] [Related]
29. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.
Burmeister K; Quagliata L; Andreozzi M; Eppenberger-Castori S; Matter MS; Perrina V; Grobholz R; Jochum W; Horber D; Moosmann P; Lehmann F; Köberle D; Ng CK; Piscuoglio S; Tornillo L; Terracciano LM
PLoS One; 2017; 12(4):e0175563. PubMed ID: 28403223
[TBL] [Abstract][Full Text] [Related]
32. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
33.
Alos L; Fuster C; Castillo P; Jares P; Garcia-Herrera A; Marginet M; Agreda F; Arance A; Gonzalvo E; Garcia M; Puig S; Teixido C
Ann Transl Med; 2020 Oct; 8(19):1218. PubMed ID: 33178750
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.
Zheng F; Dang J; Zha H; Zhang B; Lin M; Cheng F
Biomed Res Int; 2017; 2017():1293201. PubMed ID: 29250533
[TBL] [Abstract][Full Text] [Related]
35. Interferon Signaling Is Frequently Downregulated in Melanoma.
Alavi S; Stewart AJ; Kefford RF; Lim SY; Shklovskaya E; Rizos H
Front Immunol; 2018; 9():1414. PubMed ID: 29977240
[TBL] [Abstract][Full Text] [Related]
36. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Malissen N; Macagno N; Granjeaud S; Granier C; Moutardier V; Gaudy-Marqueste C; Habel N; Mandavit M; Guillot B; Pasero C; Tartour E; Ballotti R; Grob JJ; Olive D
Oncoimmunology; 2019; 8(12):e1665976. PubMed ID: 31741766
[TBL] [Abstract][Full Text] [Related]
37. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
[TBL] [Abstract][Full Text] [Related]
38. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
D'Arrigo P; Russo M; Rea A; Tufano M; Guadagno E; Del Basso De Caro ML; Pacelli R; Hausch F; Staibano S; Ilardi G; Parisi S; Romano MF; Romano S
Oncotarget; 2017 Sep; 8(40):68291-68304. PubMed ID: 28978117
[TBL] [Abstract][Full Text] [Related]
39. Correlation of MET and PD-L1 Expression in Malignant Melanoma.
Song KY; Desar S; Pengo T; Shanley R; Giubellino A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32659961
[TBL] [Abstract][Full Text] [Related]
40. Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors.
Pimenta J; Prada J; Pires I; Cotovio M
Animals (Basel); 2023 Dec; 14(1):. PubMed ID: 38200779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]